This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Diagnostic Value of Fecal Calprotectin in Disorders of the Upper Gastrointestinal Tract

This study has been completed.
Information provided by:
University Hospital, Basel, Switzerland Identifier:
First received: June 12, 2009
Last updated: January 11, 2010
Last verified: January 2010
Fecal calprotectin is a very sensitive non-invasive inflammation marker in the detection of inflammatory bowel disease and, to a lesser degree, has also proven to be useful in adenomatous polyps, neoplasias, and infectious gastroenteritis. Elevated calprotectin levels can also be found in patients with lesion only in the upper gastrointestinal tract. However, the diagnostic value of calprotectin has never been tested in this setting. The aim of the study is therefore to determine the diagnostic value of fecal calprotectin in patients with diseases of the upper gastrointestinal tract.

Peptic Esophagitis Peptic Ulcer Functional Dyspepsia Irritable Bowel Syndrome Inflammatory Bowel Diseases

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Value of Fecal Calprotectin in Upper Gastrointestinal Disease

Resource links provided by NLM:

Further study details as provided by University Hospital, Basel, Switzerland:

Biospecimen Retention:   Samples Without DNA
Biopsy samples (stomach, duodenum) will be stored by the Department of Pathology at the University Hospital Basel

Enrollment: 287
Study Start Date: March 2008
Study Completion Date: December 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
300 consecutive patients undergoing upper endoscopy at the Department of Gastroenterology & Hepatology at the University Hospital Basel

Inclusion Criteria:

  • All patients referred for upper gastrointestinal endoscopy for any reason
  • Older than 18 years

Exclusion Criteria:

  • Patients who are not able to provide informed consent
  • Patients who are not able to provide a stool sample
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00920400

Department of Gastroenterology & Hepatology
Basel, Basel-Stand, Switzerland, 4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Principal Investigator: Christoph Beglinger, Prof. University Hospital, Basel, Switzerland
  More Information

Responsible Party: Professor Christoph Beglinger, Head of Gastroenterology & Hepatology, University Hospital Basel Identifier: NCT00920400     History of Changes
Other Study ID Numbers: CALPROTECT
Study First Received: June 12, 2009
Last Updated: January 11, 2010

Additional relevant MeSH terms:
Irritable Bowel Syndrome
Inflammatory Bowel Diseases
Peptic Ulcer
Gastrointestinal Diseases
Esophagitis, Peptic
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Digestive System Diseases
Esophageal Diseases
Signs and Symptoms, Digestive
Signs and Symptoms
Duodenal Diseases
Stomach Diseases processed this record on August 23, 2017